Cost of Human Immunodeficiency Virus (HIV) and Determinants of Healthcare Costs in HIV-Infected Treatment-Naive Patients Initiated on Antiretroviral Therapy in Germany: Experiences of the PROPHET Study

Frederik Valbert(University of Duisburg-Essen), Anja Neumann(University of Duisburg-Essen), Jürgen Wasem(Alfried Krupp von Bohlen und Halbach Foundation), Kathrin Pahmeier(University of Duisburg-Essen), Nikola Hanhoff, Eva Wolf(MUC Research (Germany)), Christian Hoffmann(Hochschule für Angewandte Wissenschaften Kiel), Stephan Klauke(Infektionsmedizinisches Centrum Hamburg), Stefan Preis(Goethe University Frankfurt), Knud Schewe(Robert Koch Institute)
Value in Health
August 14, 2020
10.1016/j.jval.2020.04.1836
Cited by 11

Related Papers

Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022
|New England Journal of Medicine|2022|2.2k
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
|Blood|2018|421
COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients
|Infection|2020|246
Clinical, Diagnostic, and Treatment Disparities between HIV-Infected and Non-HIV-Infected Immunocompromised Patients with <b><i>Pneumocystis jirovecii</i></b> Pneumonia
|Respiration|2018|200
Immune deficiency is a risk factor for severe COVID‐19 in people living with HIV
|HIV Medicine|2020|166